|
Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC). |
|
|
Consulting or Advisory Role - Algeta ASA; Aragon Pharmaceuticals; Astellas Pharma; Bavarian Nordic; Bayer; Bellicum Pharmaceuticals; Biscayne Pharmaceuticals; Johnson & Johnson; Medivation; Oncogenex; Pfizer; Sanofi |
Research Funding - Algeta ASA (Inst); Bayer (Inst); Johnson & Johnson (Inst); Progenics (Inst); Sanofi (Inst); Takeda (Inst) |
|
|
Honoraria - Amgen; Astellas Pharma; Bayer; Janssen |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Janssen |
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Janssen |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Janssen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Astellas Pharma; Bayer; GlaxoSmithKline; Janssen-Cilag; Pfizer; Sanofi |
Travel, Accommodations, Expenses - Astellas Pharma; GlaxoSmithKline; Janssen-Cilag; Pfizer |
|
|
Honoraria - Bayer; M2S; Novartis; Pfizer |
Travel, Accommodations, Expenses - Bayer; MSD; Pfizer |
|
Camilla Thellenberg-Karlsson |
Consulting or Advisory Role - Bayer |
Research Funding - Sanofi (Inst) |
|
|
Stock and Other Ownership Interests - Itamar medical |
Consulting or Advisory Role - Astellas Pharma; Bayer; Itamar medical; Janssen-Cilag; Novartis; Pfizer; Teva |
Speakers' Bureau - Astellas Pharma; Bayer; Janssen-Cilag; Novartis; Teva |
Research Funding - Sanofi |
|
|
Honoraria - Astellas Pharma; Janssen |
Consulting or Advisory Role - Bayer; Janssen; Novartis |
|
|
Consulting or Advisory Role - Pfizer |
Travel, Accommodations, Expenses - Pfizer |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
|
|
|
No Relationships to Disclose |